ゾレドロン酸
分子式: | C5H10N2O7P2 |
その他の名称: | CGP-42446、2-(1H-Imidazol-1-yl)-1-hydroxyethylidenebisphosphonic acid、ゾレドロン酸、Zoledronic acid、[1-Hydroxy-2-(1H-imidazole-1-yl)ethylidene]bisphosphonic acid、ゾレドロナート、Zoledronate、1-Hydroxy-2-(1H-imidazole-1-yl)ethylidenebisphosphonic acid、[2-(1H-Imidazole-1-yl)-1-hydroxyethylidene]bisphosphonic acid、[1-Hydroxy-2-(1H-imidazole-1-yl)ethane-1,1-diyl]bisphosphonic acid、[1-Hydroxy-2-(1-imidazolyl)ethylidene]bisphosphonic acid、1-Hydroxy-2-(1H-imidazole-1-yl)ethane-1,1-diylbis(phosphonic acid) |
体系名: | 2-(1H-イミダゾール-1-イル)-1-ヒドロキシエタン-1,1-ジイルビス(ホスホン酸)、2-(1H-イミダゾール-1-イル)-1-ヒドロキシエチリデンビスホスホン酸、[1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エチリデン]ビスホスホン酸、1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エチリデンビスホスホン酸、[2-(1H-イミダゾール-1-イル)-1-ヒドロキシエチリデン]ビスホスホン酸、[1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エタン-1,1-ジイル]ビスホスホン酸、[1-ヒドロキシ-2-(1-イミダゾリル)エチリデン]ビスホスホン酸、1-ヒドロキシ-2-(1H-イミダゾール-1-イル)エタン-1,1-ジイルビス(ホスホン酸) |
ゾレドロン酸
ゾレドロン酸
(zoledronic acid から転送)
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2023/01/28 23:52 UTC 版)
ゾレドロン酸(Zoledronic acid)またはゾレドロネート(Zoledronate)は、ビスホスホネート系製剤の1つであり白色の結晶性化合物。経静脈投与で使用される。骨粗鬆症や、悪性腫瘍の合併症としての高カルシウム血症などの治療に用いられる。日本での商品はリクラストまたはゾメタ[1]。
- ^ a b 「リクラスト点滴静注液5mg」の国内製造販売承認取得について 2016年9月28日 旭化成ファーマ株式会社 2016年9月28日閲覧
- ^ Aclasta label- Australia
- ^ Jordão FM, Saito AY, Miguel DC, et al. (2011-05). “In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum.”. Antimicrob Agents Chemother. 55 (5): 2026–31. doi:10.1128/AAC.01820-10. PMID 21357292 2015年8月8日閲覧。.
- ^ a b c “ゾメタ点滴静注4mg/5mL 添付文書” (2016年5月). 2016年6月28日閲覧。
- ^ “Zoledronic acid (calcium and bone metabolism medicines)”. National Prescribing Service (2009年). 2015年8月8日閲覧。
- ^ Zomera prescribing information
- ^ Wardley, Davidson (2005-05-03). “Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.”. Br J Cancer. 92 (10): 1869–76. doi:10.1038/sj.bjc.6602551. PMID 15870721 2015年8月8日閲覧。.
- ^ a b c ゾメタ添付文書 ノバルティス製薬 2016年9月30日閲覧
- ^ “FDA Approves Reclast to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing”. Drug.com (2009年6月). 2015年8月8日閲覧。
- ^ a b リクラスト点滴静注液5mg 添付文書
- ^ “Paget's Disease of Bone”. 2015年7月9日閲覧。
- ^ ACLASTA Zoledronic acid Consumer Medicine Information
- ^ Zometa 4mg/5ml Concentrate for Solution for Infusion
- ^ Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment
- ^ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000595/smops/Positive/human_smop_000319.jsp&mid=WC0b01ac058001d127
- ^ Durie BG, Katz M, Crowley J (2005). “Osteonecrosis of the jaw and bisphosphonates”. N. Engl. J. Med. 353 (1): 99–102; discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365.
- ^ a b http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/04/human_pha_detail_000027.jsp&mid=WC0b01ac058001d126
- ^ Koto K, Murata H, Kimura S, et al. (July 2010). “Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents”. Oncol. Rep. 24 (1): 233–9. doi:10.3892/or_00000851. PMID 20514467.
- ^ Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002). “Intravenous zoledronic acid in postmenopausal women with low bone mineral density”. N. Engl. J. Med. 346 (9): 653–61. doi:10.1056/NEJMoa011807. PMID 11870242.
- ^ Black et al.. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 2007;356;18;1809-1822. Abstract
- ^ Lyles K, et al. (2007). “Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture”. N. Engl. J. Med. 357 (18): 1799–809. doi:10.1056/NEJMoa074941. PMID 17878149.
- ^ Lee YK, Ha YC, Cho YJ, et al. (2015-07-15). “Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis? A Prospective, Randomized, Open-Label, Multicenter Study.”. J Bone Joint Surg Am. 97 (14): 1142-8. doi:10.2106/JBJS.N.01157. PMID 26178889 2015年8月8日閲覧。.
- ^ PMID 19213681 Gnant, Mlineritsch. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691 February 12, 2009 Full Free Text [1]
- ^ Coleman RE, Winter MC, Cameron D, et al. (March 2010). “The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer”. Br. J. Cancer 102 (7): 1099–105. doi:10.1038/sj.bjc.6605604. PMC 2853093. PMID 20234364 .
- ^ Brufsky A, Bundred N, Coleman R, et al. (May 2008). “Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole”. Oncologist 13 (5): 503–14. doi:10.1634/theoncologist.2007-0206. PMC 1069061. PMID 18515735 .
- ^ Tonyali O, Arslan C, Altundag K (November 2010). “The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives”. Expert Opin Pharmacother 11 (16): 2715–25. doi:10.1517/14656566.2010.523699. PMID 20977404.
- ^ Brufsky A, Bundred N, Coleman R, et al. (May 2008). “Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole”. Oncologist 13 (5): 503–14. doi:10.1634/theoncologist.2007-0206. PMC 1069061. PMID 18515735 .
- ^ Phase III Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy (NATAN)
- ^ http://www.cancer.gov/clinicaltrials/search/view?cdrid=437061&version=healthprofessional
- ^ Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M (August 2010). “Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer”. Clin. Breast Cancer 10 (4): 267–74. doi:10.3816/CBC.2010.n.034. PMID 20705558.
- ^ Vondracek, S. F. (2010). “Managing osteoporosis in postmenopausal women”. American Journal of Health-System Pharmacy 67 (7 Suppl 3): S9–19. doi:10.2146/ajhp100076. PMID 20332498.
- 1 ゾレドロン酸とは
- 2 ゾレドロン酸の概要
- 3 研究開発
- 4 禁忌
- zoledronic acidのページへのリンク